Skip to content
KYTX·Nasdaq·US

Kyverna Therapeutics

Kyverna Therapeutics is a late-stage clinical biopharmaceutical company that develops cell therapies, including its lead product candidate miv-cel (KYV-101), an anti-CD19 autologous CAR T-cell therapy, for patients with autoimmune diseases such as stiff person syndrome and generalized myasthenia gravis.

Source: SEC 10-K Mar 26, 2026

Thematic Position

KYTX

Relationship Groups

Partners2
Licensing1
Competitors11

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

8 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade policy
U.S. and Chinese reciprocal tariffs may raise Kyverna's supply costs
SEC 10-KMar 26, 2026

The full regulatory passage is part of the Pro plan.

14 more · Regulatory and geopolitical insights are part of the Pro plan.